We show that both TCRm anti-KRASG12V CAR-redirected T and NK cells demonstrated specific IFN-γ release and cytolytic activity upon recognition of KRASG12V5-14 peptide loaded onto HLA-A2 expressing T2 cells or KRASG12V positive tumor cells. The gene discussed is IFNG; the disease is neoplasm.